VitaSpring Biomedical Co Ltd Ordinary Shares VSBC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $15.00
- Day Range
- $15.00–15.00
- 52-Week Range
- $11.01–16.00
- Bid/Ask
- $8.00 / $18.15
- Market Cap
- $3.10 Bil
- Volume/Avg
- 943 / 943
Key Statistics
- Price/Earnings (Normalized)
- 3,629.76
- Price/Sales
- 664.53
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
VitaSpring Biomedical Co Ltd is a start-up business company. The company's objective is to develop new drugs in cell medicine. The company also plans to produce X.MSC cytopharmaceuticals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.vitaspringbio.com
Comparables
Valuation
|
Metric
|
VSBC
|
ACLX
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 3,629.76 | — | — |
Price/Book Value | 1,908.62 | 5.69 | 0.97 |
Price/Sales | 664.53 | 23.01 | — |
Price/Cash Flow | 2,904.34 | — | — |
Price/Earnings
VSBC
ACLX
EQRX
Financial Strength
|
Metric
|
VSBC
|
ACLX
|
EQRX
|
|---|---|---|---|
Quick Ratio | 4.32 | 5.94 | 18.43 |
Current Ratio | 4.33 | 6.06 | 18.78 |
Interest Coverage | — | −23.39 | — |
Quick Ratio
VSBC
ACLX
EQRX
Profitability
|
Metric
|
VSBC
|
ACLX
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | 42.38% | −6.26% | −15.72% |
Return on Equity (Normalized) | 65.38% | −12.08% | −16.71% |
Return on Invested Capital (Normalized) | 55.23% | −13.11% | −21.31% |
Return on Assets
VSBC
ACLX
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tkxqcjfxh | Xlql | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ddftshlr | Jghrmz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hzghktkgn | Cvqfvj | $97.8 Bil | |
MRNA
| Moderna Inc | Qcszxsd | Mhznf | $38.8 Bil | |
ARGX
| argenx SE ADR | Fkdwcydt | Vhv | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Pdzmrlxd | Lffy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wgkxpzxcf | Nttvs | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ngskvrdm | Mnymp | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rqhkdvzrqq | Kxtmbt | $12.5 Bil | |
INCY
| Incyte Corp | Mhdnjwrfz | Xmllv | $11.5 Bil |